

CORPORATE FACT SHEET

www.artesmedical.com

www.artefill.com

December 2006

Profile: Artes Medical, Inc. is a medical technology company focused on developing, manufacturing, and commercializing a new category of non-resorbable aesthetic injectable products for the dermatology and plastic surgery markets. The Company's initial product, ArteFill®, was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for the correction of facial wrinkles known as smile lines, or nasolabial folds.

Ownership: Founded in 1999, Artes Medical, Inc. is publicly traded (NASDAQ: ARTE).

Office: Corporate headquarters are located at 5870 Pacific Center Blvd., San Diego, California 92121.

Management:


- Christopher J. Reinhard**, *Executive Chairman of the Board of Directors*
- Diane S. Goostree**, *President & Chief Executive Officer*
- Peter C. Wulff**, *Chief Financial Officer*
- Karla R. Kelly, RN, JD**, *Chief Legal Officer, General Counsel & Corporate Secretary*
- Adelbert L. Stagg, PhD**, *VP, Regulatory Affairs & Quality and Chief Compliance Officer*
- Russell J. Anderson**, *VP, Product Development & Engineering*
- Larry J. Braga**, *VP, Manufacturing*
- Susan A. Brodsky-Thalken**, *VP, U.S. Sales & Training*
- Frank M. Fazio**, *VP, Marketing & International Markets*

Principal Product: Artes Medical's lead product is ArteFill, the first FDA-approved non-resorbable aesthetic injectable implant. ArteFill is indicated for the correction of facial wrinkles known as nasolabial folds, or smile lines. ArteFill consists of a proprietary combination of ArteFill Precision-Filtered Microspheres™ suspended in a carrier gel containing ArteFill Purified Bovine Collagen™ with 0.3 percent lidocaine. The microspheres are made of polymethylmethacrylate (PMMA), one of the most commonly used artificial implant materials in medicine. Following injection, the microspheres remain intact at the injection site and provide a permanent structure to support the wrinkle and help prevent further wrinkling. As a result, ArteFill provides patients with aesthetic benefits that may last for years.

Trial Results: Data from Artes Medical's controlled, multi-center clinical trial in 251 patients demonstrated the safety and efficacy of ArteFill. Smile lines treated with ArteFill showed a significantly greater and persistent improvement compared to those treated with the collagen control (Zyplast®). The following graph (next page) depicts those patients receiving treatment of their nasolabial folds (n=212). The clinical study results compare the wrinkle correction in patients treated with ArteFill versus patients treated with the control collagen. One month after treatment, both ArteFill and the collagen control had a similar effect on

improving smile line wrinkles. At the 3 month evaluation, the patients treated with ArteFill maintained their wrinkle correction, while the patients treated with the collagen control started to return to their pre-treatment status. At the 6 month evaluation, which was the primary efficacy evaluation period, the wrinkle correction in the patients treated with ArteFill persisted, while the patients treated with the collagen control returned to their pre-treatment status. At the 6 month evaluation, in accordance with the clinical trial protocol, the control group patients were offered the opportunity to be treated with ArteFill. Ninety-one percent of these patients chose to be treated with ArteFill. ArteFill patients were evaluated one year after treatment, and demonstrated continued safety and wrinkle correction. Because the control group patients had returned to their pre-treatment status or were subsequently treated with ArteFill, Artes Medical did not evaluate these patients at 12 months. Throughout the clinical trial, there was no significant difference in the safety profiles of ArteFill and the collagen control.

Nasolabial Fold Improvement



Safety Profile:

Adverse Events Reported at an Incidence of 1% or Greater in U.S. Clinical Trials of ArteFill

| Event | Number of Events (Events/subjects treated, %) | | |
|---|--|-----------------------------|------------------------------|
| | ArteFill ¹ n=285 | ArteFill ² n=106 | Control ^{3,4} n=123 |
| Lumpiness at injection area more than one month after injection | 13 (4.6) | – | 4 (3.3) |
| Persistent swelling or redness | 10 (3.5) | 3 (2.8) | 13 (10.6) |
| Increased sensitivity | 5 (1.8) | 2 (1.9) | – |
| Rash, itching more than 48 hours after injection | 4 (1.4) | – | 2 (1.6) |
| Sensitization reactions | – | – | 6 (4.9) |
| Abscess | – | – | 3 (2.4) |
| Visibility of puncture area | – | – | 2 (1.6) |

¹ 128 ArteFill subjects in the controlled study and 157 subjects in an open label study, who were followed for 1 year after implantation.
² 106 Control subjects who received ArteFill in the cross-over arm of the controlled study and were followed for 6 months after implantation.
³ 123 subjects who received the Control treatment in the controlled study and were followed for 6 months after implantation.
⁴ The Control treatment in the study was a commercially available collagen implant (Zyplast®).

No Severe Adverse Events Reported with ArteFill in U.S. Pivotal Clinical Trial (n=251)

| Type of Events | ArteFill (n=128) | | | | Collagen Control (n=123) | | | |
|---|------------------|----------|----------|-----------|--------------------------|-----------|-----------|-----------|
| | Mild | Moderate | Severe | Total | Mild | Moderate | Severe | Total |
| Events localized to injection site ⁺ | 18 (1*) | 4 | – | 22 | 13 (2*) | 12 | 8 | 33 |
| Granuloma and/or enlargement of implant ⁺⁺ | – | – | – | – | – | – | 1 | 1 |
| Systemic events ^{**} | 1 | 3 (1*) | – | 4 | 1 (1*) | – | – | 1 |
| Severe illness, trauma, death | – | – | – | – | – | – | 1 (1*) | 1 |
| Total AEs | 19 | 7 | 0 | 26 | 14 | 12 | 10 | 36 |

* The number outside of the parentheses are the Total AEs, the number within the parentheses are the subset within the Total that are deemed NOT related to the implant by the investigator.
⁺ This includes two reactions recorded as AEs that also required "removal or drainage"; one ArteFill AE (mild) treated by removal where pathology showed no foreign body reaction and one collagen control AE (severe) treated by incision & drainage, no pathology available.
^{**} Blurred vision, recurrence of existing herpes labialis, flu-like symptoms, other systemic complications.
⁺⁺ This includes one collagen AE (severe) which required "removal or drainage"; treated by incision & drainage, no pathology available.



Other Applications: We believe our proprietary platform technology consisting of precision-filtered injectable microspheres and purified bovine collagen may have applications outside the aesthetic market, including the potential treatment of gastroesophageal reflux disease (GERD) and stress urinary incontinence (SUI). We intend to explore these non-aesthetic applications through collaborative arrangements with strategic partners. These potential indications and new product formulations are in pre-clinical development and have not been approved or cleared for marketing.

Intellectual Property: Artes Medical relies on a combination of patent, trademark, copyright, trade secret and other intellectual property laws, non-disclosure agreements and other measures to protect its proprietary rights in both the United States and foreign markets.

••••• **Media Contacts:**

Corporate Media
Nigel Smith or Risa Goldman Burgess
Schwartz Communications
415.512.0770 or 781.684.0770
artes@schwartz-pr.com

Consumer Media
Lauren Rodolitz
Behrman Communications
212.986.7000
artes@behrmanpr.com

FREQUENTLY ASKED QUESTIONS

What is ArteFill®?

ArteFill is the first FDA-approved, non-resorbable aesthetic injectable implant for the correction of facial wrinkles known as nasolabial folds, or smile lines. ArteFill consists of a proprietary combination of ArteFill Precision-Filtered Microspheres™ suspended in a carrier gel containing ArteFill Purified Bovine Collagen™ with 0.3 percent lidocaine for patient comfort during injection.

How does ArteFill work?

ArteFill is a unique dual-acting permanent aesthetic injectable implant that provides both immediate and enduring cosmetic benefits. First, ArteFill visibly corrects the smile line by providing volume beneath the wrinkle, similar to other dermal fillers. Unlike temporary dermal fillers, ArteFill contains microspheres that provide the permanent support structure required to sustain the wrinkle correction. The microspheres are made of polymethylmethacrylate (PMMA), one of the most widely used synthetic implant materials in medicine. Studies have shown that PMMA microspheres are both biocompatible and safe for use as soft tissue fillers. Since macrophages and human enzymes are unable to break down PMMA, the microspheres are not degraded or absorbed by the body. The microspheres are 30 to 50 microns in diameter, barely visible to the naked eye, and are suspended in a purified bovine collagen carrier gel. Once injected, the microspheres reside permanently at the injection site for persistent wrinkle correction.

What is PMMA?

PMMA or polymethylmethacrylate [pol-ee-meth-uhl-meth-ak-ruh-leyt] is a biocompatible synthetic polymer manufactured to the standards required for use as a long-term medical grade implant, similar to what is commonly used in intraocular lenses (IOL's).

How is ArteFill different from Botox® Cosmetic and temporary dermal fillers?

Botox Cosmetic (e.g., Botulinum Toxin) is a temporary muscle-paralyzing drug, not a dermal filler. Botox Cosmetic is injected directly into the target muscle to block the nerve signals from the brain to the muscles so that they cannot contract. Wrinkles then gradually become smoother due to disuse. The effects last for approximately three to four months.

Temporary dermal fillers are made of different kinds of natural or synthetic materials that have been developed over the years for injection into the skin. The materials in these products are completely metabolized and absorbed by the body over time. As a result, the aesthetic benefits of these temporary dermal fillers decrease over time, and generally last up to six months.

Unlike Botox and existing temporary dermal fillers, ArteFill contains microspheres made of PMMA. These microspheres are not absorbed or degraded by the human body. Following injection, the PMMA microspheres in ArteFill remain intact at the injection site and provide a permanent structure to support the wrinkle and help prevent further wrinkling. As a result, we believe that ArteFill will provide patients with aesthetic benefits that may last for years. This innovative technology platform has created a new category of aesthetic injectable product known as Permanent Aesthetic Injectable Implant™.

How is ArteFill administered?

ArteFill is administered in a physician's office and typically requires only 15 to 30 minutes (i.e., lunch time procedure). The in-office treatment for ArteFill is similar to that of injectable temporary dermal fillers, but the results are expected to last for years.

How did ArteFill perform in clinical studies?

Clinical trials in the United States were successfully completed and were the basis for ArteFill's FDA approval. These studies showed that ArteFill was safe, effective and predictable for the correction of facial wrinkles known as nasolabial folds, or smile lines. Improvement in nasolabial folds treated with ArteFill was significantly greater as compared to the collagen control. One month after treatment, both ArteFill and the collagen control had a similar effect on improving smile line wrinkles. At the 3 month evaluation, the patients treated with ArteFill maintained their wrinkle correction, while the patients treated with the collagen control started to return to their pre-treatment status. At the 6 month evaluation, which was the primary efficacy evaluation period, the wrinkle correction in the patients treated with ArteFill persisted, while the patients treated with the collagen control returned to their pre-treatment status. At the 6 month evaluation, in accordance with the clinical trial protocol, the control group patients were offered the opportunity to be treated with ArteFill. Ninety-one (91%) percent of these patients chose to be treated with ArteFill. ArteFill patients were evaluated one year after treatment, and demonstrated continued safety and wrinkle correction. Because the control group patients had returned to their pre-treatment status or were subsequently treated with ArteFill, Artes Medical did not evaluate these patients at 12 months. Throughout the clinical trial, there was no significant difference in the safety profiles of ArteFill and the collagen control.

What is the difference between ArteFill® and Artecoll®?

ArteFill is a third generation product manufactured and distributed exclusively by Artes Medical at its dedicated manufacturing facility in San Diego, California. Artecoll, a second generation product, is manufactured and distributed by Rofil Medical International B.V. in Breda, The Netherlands. Artes Medical has never manufactured or marketed Artecoll in any country, and has never received any economic benefit from the manufacture or distribution of Artecoll.

ArteFill's formulation meets the rigorous FDA quality requirements for both the bovine collagen carrier and the PMMA microspheres. The bovine collagen carrier is sourced from a closed herd located in the United States. ArteFill's PMMA microspheres are precision-filtered to yield round, smooth and uniformly sized microspheres (30 to 50 microns). The content of small, potentially phagocytized microspheres (<20 microns) must be less than 1% by number. This FDA requirement contrasts with Artecoll, whose content of small particles is <1% by volume.

Who offers ArteFill?

The Company intends that only those dermatologists, plastic surgeons and cosmetic surgeons who have successfully completed the formalized training program will offer ArteFill treatments. Our program includes training on the proper injection technique for ArteFill and ArteFill Progressive Enhancement™, which is designed to provide stages of wrinkle correction tailored to each patient's aesthetic improvement goals. The goal of the training program is to maximize patient and physician satisfaction with ArteFill by fostering consistent and high-quality treatments.



How can physicians and patients learn more about ArteFill?

Patients and physicians can learn more about ArteFill by visiting the ArteFill web site, www.artefill.com or the Artes Medical web site, www.artesmedical.com.

Will ArteFill be used for other applications?

ArteFill is currently approved for the treatment of facial wrinkles known as nasolabial folds, or smile lines. We believe our proprietary platform technology consisting of our precision-filtered injectable microspheres and purified bovine collagen may have applications outside the aesthetic market, including the potential treatment of gastroesophageal reflux disease (GERD) and stress urinary incontinence (SUI). We intend to explore these non-aesthetic applications through collaborative arrangements with strategic partners. These potential indications and new product formulations are in pre-clinical development and have not been approved or cleared for marketing.



ArteFill®. The First To Last™.

Changing the Face of the Aesthetic Injectable Market

Artes Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing a new category of Permanent Aesthetic Injectable Implant™ for the dermatology and plastic surgery markets. Artes Medical's initial product, ArteFill®, was approved in October 2006 by the U.S. Food and Drug Administration (FDA) for the correction of facial wrinkles known as nasolabial folds, or smile lines.

ArteFill consists of a proprietary combination of ArteFill Precision-Filtered Microspheres™ suspended in a carrier gel containing ArteFill Purified Bovine Collagen™ with 0.3 percent lidocaine. Lidocaine is used to alleviate patient discomfort during injection. The microspheres are made of polymethylmethacrylate (PMMA), one of the most commonly used artificial implant materials in medicine. The microspheres have a diameter between 30 to 50 microns, barely visible to the naked eye, to prevent migration from the injection site. When injected under a smile line, the tiny microspheres provide a permanent support matrix for enduring wrinkle correction.

Data from Artes Medical's controlled, multi-center clinical trials demonstrated the safety and efficacy of ArteFill. Smile lines treated with ArteFill showed a significantly greater and persistent improvement compared to those treated with the collagen control. At 6 months, patients treated with ArteFill showed a sustained effect, while the patients treated with the collagen control returned to their pre-treatment wrinkle severity. ArteFill patients were evaluated for one year after treatment, and demonstrated continued safety and wrinkle correction. Because the control group patients had returned to their pre-treatment status or were subsequently treated with ArteFill, Artes Medical did not evaluate these patients at 12 months. Throughout the clinical trial, there was no significant difference in the safety profiles of ArteFill and the collagen control.

The ArteFill Physician Training Program will provide clinicians with training in the injection technique used to inject ArteFill. This injection technique is similar to the technique currently used with many temporary dermal fillers. ArteFill Progressive Enhancement™ allows clinicians to provide stages of wrinkle correction tailored to the patient's aesthetic improvement goals.

ArteFill is designed to improve patient satisfaction and answer the growing demand for a safe and enduring treatment option for the correction of smile line wrinkles. Many patients experience "injection-fatigue" and "credit card-fatigue" as a result of the continuous re-injections required with Botox® Cosmetic and existing temporary dermal fillers. Since the microspheres in ArteFill are permanent, the results are expected to be enduring. ArteFill injections are generally performed as a 15 to 30 minute in-office procedure.

Management Team Biographies

Christopher J. Reinhard

Executive Chairman of the Board of Directors

Christopher J. Reinhard has been our Executive Chairman of the Board of Directors since June 2004. Since December 2003, Mr. Reinhard has also served as Chairman of the Board and Chief Executive Officer of Cardium Therapeutics, Inc., a public biotechnology company. From July 2002 to December 2004, Mr. Reinhard served as Chief Executive Officer of Collateral Therapeutics, Inc., a public biotechnology company. Prior to the acquisition of Collateral Therapeutics, Inc. by Schering AG in July 2002, Mr. Reinhard worked for Collateral Therapeutics in a variety of roles from June 1995 to July 2002, including Chief Financial Officer and President. Mr. Reinhard holds a B.S. in Finance and an M.B.A. from Babson College.

Diane S. Goostree

President and Chief Executive Officer

Diane S. Goostree has been our Chief Executive Officer since November 2006 and our President since March 2006. She also served as our Chief Operating Officer from March 2006 to November 2006. From September 2002 to February 2006, Ms. Goostree was employed with SkinMedica, Inc., a dermatology specialty pharmaceutical company, most recently serving as Senior Vice President, Corporate Development and Operations. From May 2002 to September 2002, Ms. Goostree served as a consultant for SkinMedica, Inc. From November 2000 to May 2002, Ms. Goostree served as Vice President, Business Development at Elan Pharmaceuticals, a biotechnology company. Prior to that, Ms. Goostree worked for Dura Pharmaceuticals in a variety of roles, including Regional Sales Director, and most recently as Vice President of Business Development from September 1995 until its acquisition by Elan Pharmaceuticals in November 2000. Ms. Goostree holds a B.S. in Chemical Engineering from the University of Kansas and an M.B.A. from the University of Missouri in Kansas City.

Peter C. Wulff

Chief Financial Officer

Peter C. Wulff has been our Chief Financial Officer since January 2005. From May 2001 to May 2004, Mr. Wulff served as Vice President Finance, Chief Financial Officer, Treasurer and Assistant Secretary of CryoCor, Inc., a medical device company. From November 1999 to May 2001, Mr. Wulff was Chief Financial Officer and Treasurer at Natural Alternatives International, Inc., a public and international nutritional supplement manufacturer. Mr. Wulff holds a B.A. in both Economics and Germanic Languages and an M.B.A. in Finance from Indiana University. Mr. Wulff is also a Certified Management Accountant.

Karla R. Kelly R.N., J.D.

Chief Legal Officer, General Counsel and Corporate Secretary

Karla R. Kelly has been our Chief Legal Officer since June 2006. Prior to that, she was our Vice President, Legal Affairs from December 2005 to June 2006. She also has been our General Counsel and Corporate Secretary since December 2005. Ms. Kelly has provided legal services to us since 1999. Prior to joining us, Ms. Kelly practiced out of her own law firm, Karla R. Kelly, a Professional Law Corporation, from February 2003 to December 2005. From August 1998 to January 2003, Ms. Kelly practiced as Special Counsel with the law firm of Luce Forward Hamilton & Scripps LLP in San Diego, California. Ms. Kelly holds a B.A. in Nursing from the College of St. Catherine and a J.D. from the George Washington University National Law Center.

Adelbert L. Stagg, Ph.D.

Vice President of Regulatory Affairs & Quality and Chief Compliance Officer

Adelbert L. Stagg, Ph.D. has been our Vice President, Regulatory Affairs & Quality and Chief Compliance Officer since March 2005. From August 1998 to March 2005, Dr. Stagg served as Senior Director, Regulatory Affairs of Allergan, Inc., a public pharmaceutical company. In 1999, Dr. Stagg was the recipient of the "Hammer Award" from the Vice President of the United States of America for industry leadership in working with the FDA. Dr. Stagg holds a B.A. in both Zoology and History from Andrews University and a Ph.D. in both Physiology and Pharmacology from Duke University. He also completed a postdoctoral fellowship in the department of cardiology at Duke University.

Russell J. Anderson

Vice President of Product Development and Engineering

Russell J. Anderson has been our Vice President, Product Development and Engineering since June 2005. From February 2004 to May 2005, he served as our Vice President, Engineering and Manufacturing. Mr. Anderson was a Project Engineer at NuVasive, Inc., a medical device company, from February 2003 to February 2004. From October 2002 to November 2003, Mr. Anderson was also a product development consultant for Boston Scientific Corp. and Target Therapeutics, Inc., both medical device companies. From April 2001 to October 2002, Mr. Anderson was Director of Engineering at Novare Surgical Systems, Inc., a medical device company. Mr. Anderson holds a B.S. in Environmental Engineering from California Polytechnic State University and an M.B.A. from California State University in Hayward.

Larry J. Braga

Vice President of Manufacturing

Larry J. Braga has been our Vice President, Manufacturing since June 2005 and previously served as Senior Director, Collagen Manufacturing since June 2004. From April 2000 to May 2004, he served as Director of Manufacturing at Anosys, Inc., a privately held vaccine development company. From November 1997 to April 2000, Mr. Braga served as Senior Process Engineer at Cohesion Technologies Inc., a public medical device company. Mr. Braga holds a B.S. in Biological Sciences from California State University in Hayward. He also holds a California pharmacy exemptee license.

Susan A. Brodsky-Thalken

Vice President of U.S. Sales and Training

Susan A. Brodsky-Thalken has been our Vice President, U. S. Sales and Training since October 2006. From April 2006 to October 2006, she served as our Executive Director, U.S. Marketing and Aesthetic Market Development. From February 2003 to April 2006, Ms. Brodsky-Thalken was a principal at AAP, Inc. providing consulting services to the aesthetic medical device industry. From April 2002 to January 2003, Ms. Brodsky-Thalken served as Vice President, Sales of INAMED Corporation, a public medical device company. From February 1995 to March 2002, Ms. Brodsky-Thalken served as Regional Sales Director for INAMED Corporation. Ms. Brodsky-Thalken studied Biological Science at San Francisco State University.

Frank M. Fazio

Vice President of Marketing and International Markets

Frank M. Fazio has been our Vice President of Marketing since June 2006. From March 2005 to May 2006, Mr. Fazio served as Director, Market Development of INAMED Corporation, a public medical device company. From May 2002 to March 2005, Mr. Fazio served as Director, Facial Aesthetics of INAMED Corporation. From April 2001 to May 2002, Mr. Fazio was a Principal at AMC Consulting, providing consulting services to companies in the medical device industry. Mr. Fazio holds a B.S. in Molecular and Cellular Biology from the University of Arizona.